Lazard Asset Management
XENT

Lazard Asset Management’s Intersect ENT, Inc XENT Stock Holding History

Lazard Asset Management’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,918
Closed -$52K – 2526
2021
Q3 		$52K Buy
+1,918
New +$47.4K ﹤0.01% 1675

Other funds holding XENT

VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
KLCMU
Kite Lake Capital Management (UK) London, United Kingdom $125M AUM 198.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Lazard Asset Management's XENT Position: Q4 2021 in Review

Lazard Asset Management sold out of Intersect ENT, Inc (XENT) in Q4 2021, closing a stake of 1,918 shares — an estimated $52K sold.

Lazard Asset Management first reported a position in XENT in Q3 2021 and held it in 1 quarter. The position peaked at $52K in Q3 2021. 121 funds tracked by Wall St. Rank hold XENT as of Q4 2021.

  • Lazard Asset Management reported no remaining Intersect ENT, Inc position as of Q4 2021 after selling out during the quarter.
  • Lazard Asset Management sold 1,918 Intersect ENT, Inc shares in Q4 2021, an estimated $52K.
  • Lazard Asset Management first reported a position in Intersect ENT, Inc in Q3 2021 and held it in 1 quarter.
  • Lazard Asset Management's Intersect ENT, Inc position peaked at $52K in Q3 2021.
  • 121 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q4 2021.

Based on Lazard Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.